Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amic has been granted a non-exclusive license under patent rights of Roche Diagnostics to commercialize a point-of-care test for NT-proBNP in the European market.
Subscribe to our email newsletter
NT-proBNP is a key cardiac marker for a broad array of cardiovascular conditions, including the diagnosis and management of heart failure, and risk stratification of patients with acute coronary syndrome.
Lars Gunneflo, CEO of Amic, said: “The NT-proBNP test will be one of the first to be launched on our Forecast POC diagnostic system.”